AmCad BioMed Corporation
AmCad BioMed Corporation develops computer-aided detection and diagnosis (CAD) software devices primarily in Taiwan. It offers products for early detection and diagnosis of various diseases. The company's products include AmCAD-UT Detection, a CAD device for ultrasound images of thyroid nodules; and AmCAD-UO for detection of obstructive sleep apnea on awake patients. It also developing AmCAD-US, … Read more
AmCad BioMed Corporation (4188) - Total Liabilities
Latest total liabilities as of December 2025: $U21.88 Million UYU
Based on the latest financial reports, AmCad BioMed Corporation (4188) has total liabilities worth $U21.88 Million UYU as of December 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
AmCad BioMed Corporation - Total Liabilities Trend (2021–2025)
This chart illustrates how AmCad BioMed Corporation's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
AmCad BioMed Corporation Competitors by Total Liabilities
The table below lists competitors of AmCad BioMed Corporation ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Samil Co.Ltd
KQ:032280
|
Korea | ₩41.68 Billion |
|
Huron Valley Bancorp Inc
PINK:HVLM
|
USA | $-23.63 Million |
|
Robit Oyj
HE:ROBIT
|
Finland | €41.74 Million |
|
Airtime Partecipazioni SpA
PA:ALMEX
|
France | €116.81 Million |
|
Hawsons Iron Ltd
AU:HIO
|
Australia | AU$1.88 Million |
|
PT MNC Energy Investments Tbk
JK:IATA
|
Indonesia | Rp102.67 Million |
|
Delta Israel Brands Ltd
TA:DLTI
|
Israel | ILA783.36 Million |
|
Pacgold Ltd
AU:PGO
|
Australia | AU$1.70 Million |
Liability Composition Analysis (2021–2025)
This chart breaks down AmCad BioMed Corporation's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 22.62 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.04 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.04 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how AmCad BioMed Corporation's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for AmCad BioMed Corporation (2021–2025)
The table below shows the annual total liabilities of AmCad BioMed Corporation from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $U21.88 Million | -29.76% |
| 2024-12-31 | $U31.16 Million | -10.21% |
| 2023-12-31 | $U34.70 Million | +1.81% |
| 2022-12-31 | $U34.08 Million | -7.19% |
| 2021-12-31 | $U36.72 Million | -- |